ENDRA Life Sciences (NDRA) Total Current Liabilities (2016 - 2026)
ENDRA Life Sciences (NDRA) posted quarterly Total Current Liabilities of $835440.0 for Q1 2026, up 47.66% year-over-year from $565785.0 in Q1 2025, and up 11.25% quarter-over-quarter from $750956.0 in Q4 2025.
ENDRA Life Sciences (NDRA) Total Current Liabilities (2016 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Total Current Liabilities for 11 consecutive years, with $835440.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 47.66% year-over-year to $835440.0; the TTM figure through Mar 2026 stood at $835440.0 (up 47.66% YoY), while the FY2025 annual figure was $750956.0, up 24.08% from the prior year.
- Total Current Liabilities climbed to $835440.0 in Q1 2026 per NDRA's latest filing, from $750956.0 in the prior quarter.
- Across five years, Total Current Liabilities topped out at $2.2 million in Q3 2023 and bottomed at $565785.0 in Q1 2025.
- Historically, Total Current Liabilities has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 77.32% — and 2024, when it tumbled 62.48%.
- ENDRA Life Sciences' Total Current Liabilities stood at $1.7 million in 2022, then tumbled by 46.99% to $903095.0 in 2023, then tumbled by 32.98% to $605230.0 in 2024, then increased by 24.08% to $750956.0 in 2025, then advanced by 11.25% to $835440.0 in 2026.
- Business Quant data shows NDRA's Total Current Liabilities at $835440.0 in Q1 2026, $750956.0 in Q4 2025, and $800307.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 15.07 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 8.11 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 1.29 Bn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 2.27 Bn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 8.82 Bn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 558.26 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 1.58 Bn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 1.20 Bn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 1.79 Bn |
| 10 | ENDRA Life Sciences | 5.44 Mn | 5.08 Mn | - | 835,440.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 835,440.00 |
| Dec 31, 2025 | 750,956.00 |
| Sep 30, 2025 | 800,307.00 |
| Jun 30, 2025 | 576,637.00 |
| Mar 31, 2025 | 565,785.00 |
| Dec 31, 2024 | 605,230.00 |
| Sep 30, 2024 | 814,045.00 |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 903,095.00 |
| Sep 30, 2023 | 2.17 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 1.71 Mn |
| Jun 30, 2022 | 1.50 Mn |
| Mar 31, 2022 | 1.36 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 1.58 Mn |
| Jun 30, 2021 | 1.64 Mn |